Zobrazeno 1 - 10
of 309
pro vyhledávání: '"Marion, De Jong"'
Publikováno v:
Royal Society Open Science, Vol 10, Iss 3 (2023)
Targeted radionuclide therapy (TRT) is a promising strategy to treat different types of cancer. TRT relies on a targeting vector used to deliver a therapeutic radionuclide specifically to the tumour site. Several low molecular weight ligands targetin
Externí odkaz:
https://doaj.org/article/830b32d9cd5f4dbdbffe95e58abad7ec
Autor:
Dylan Chapeau, Sofia Koustoulidou, Maryana Handula, Savanne Beekman, Corrina de Ridder, Debra Stuurman, Erik de Blois, Yulia Buchatskaya, Karlijn van der Schilden, Marion de Jong, Mark W. Konijnenberg, Yann Seimbille
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 985 (2023)
Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 (212Pb) r
Externí odkaz:
https://doaj.org/article/b8faf153cecd468bae494dab626614f5
Autor:
Marcus C. M. Stroet, Bianca M. Dijkstra, Sebastiaan E. Dulfer, Schelto Kruijff, Wilfred F. A. den Dunnen, Frank A. E. Kruyt, Rob J. M. Groen, Yann Seimbille, Kranthi M. Panth, Laura Mezzanotte, Clemens W. G. M. Lowik, Marion de Jong
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Background There is a growing body of nuclear contrast agents that are repurposed for fluorescence-guided surgery. New contrast agents are obtained by substituting the radioactive tag with, or adding a fluorescent cyanine to the molecular st
Externí odkaz:
https://doaj.org/article/4aebdcf478de47da9c40600858fc1dba
Autor:
Eric J. Meester, Erik de Blois, Boudewijn J. Krenning, Antonius F. W. van der Steen, Jeff P. Norenberg, Kim van Gaalen, Monique R. Bernsen, Marion de Jong, Kim van der Heiden
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Purpose Many radioligands have been developed for the visualization of atherosclerosis by targeting inflammation. However, interpretation of in vivo signals is often limited to plaque identification. We evaluated binding of some promising ra
Externí odkaz:
https://doaj.org/article/565f120e83574cff81d8656dbc65c8a4
Autor:
Giulia Tamborino, Marijke De Saint-Hubert, Lara Struelens, Dayana C. Seoane, Eline A. M. Ruigrok, An Aerts, Wiggert A. van Cappellen, Marion de Jong, Mark W. Konijnenberg, Julie Nonnekens
Publikováno v:
EJNMMI Physics, Vol 7, Iss 1, Pp 1-19 (2020)
Abstract Background Survival and linear-quadratic model fitting parameters implemented in treatment planning for targeted radionuclide therapy depend on accurate cellular dosimetry. Therefore, we have built a refined cellular dosimetry model for [177
Externí odkaz:
https://doaj.org/article/3f518fc5abf94785bb169b9564a1b55f
Autor:
Sofia Koustoulidou, Maryana Handula, Corrina de Ridder, Debra Stuurman, Savanne Beekman, Marion de Jong, Julie Nonnekens, Yann Seimbille
Publikováno v:
Pharmaceuticals, Vol 15, Iss 9, p 1155 (2022)
Somatostatin receptor subtype 2 (SSTR2) has become an essential target for radionuclide therapy of neuroendocrine tumors (NETs). JR11 was introduced as a promising antagonist peptide to target SSTR2. However, due to its rapid blood clearance, a bette
Externí odkaz:
https://doaj.org/article/8f079e48345642d6ae422b4ce72fbae7
Autor:
Maryana Handula, Marjolein Verhoeven, Kuo-Ting Chen, Joost Haeck, Marion de Jong, Simone U. Dalm, Yann Seimbille
Publikováno v:
Pharmaceutics, Vol 14, Iss 1, p 195 (2022)
Nuclear and optical dual-modality probes can be of great assistance in prostate cancer localization, providing the means for both preoperative nuclear imaging and intraoperative surgical guidance. We developed a series of probes based on the backbone
Externí odkaz:
https://doaj.org/article/b265c9f790814b438851f237abc9111e
Autor:
Maria J. Klomp, Leo J. Hofland, Lilian van den Brink, Peter M. van Koetsveld, Fadime Dogan, Corrina M. A. de Ridder, Debra C. Stuurman, Marian C. Clahsen-van Groningen, Marion de Jong, Simone U. Dalm
Publikováno v:
Pharmaceutics, Vol 14, Iss 1, p 173 (2022)
Background: To improve peptide receptor radionuclide therapy (PRRT), we aimed to enhance the expression of somatostatin type-2 receptors (SSTR2) in vitro and in vivo, using valproic acid (VPA). Methods: Human NCI-H69 small-cell lung carcinoma cells w
Externí odkaz:
https://doaj.org/article/3243ddd2fe374fbdbeed5ab236f4efc7
Autor:
Seimbille, Dylan Chapeau, Sofia Koustoulidou, Maryana Handula, Savanne Beekman, Corrina de Ridder, Debra Stuurman, Erik de Blois, Yulia Buchatskaya, Karlijn van der Schilden, Marion de Jong, Mark W. Konijnenberg, Yann
Publikováno v:
Pharmaceuticals; Volume 16; Issue 7; Pages: 985
Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 (212Pb) r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::85d2eb9a992d2392e5f70740a3476e5f
Autor:
Fijs W. B. van Leeuwen, Bart Cornelissen, Federico Caobelli, Laura Evangelista, Latifa Rbah-Vidal, Silvana Del Vecchio, Catarina Xavier, Jacques Barbet, Marion de Jong
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 2, Iss 1, Pp 1-6 (2017)
Abstract Given the increasing exploration of fluorescent tracers in the field of nuclear medicine, a need has risen for practical development guidelines that can help improve the translation aspects of fluorescent tracers. This editorial discusses th
Externí odkaz:
https://doaj.org/article/aecf421a1b7a490b8bfece6056904b72